CMH :: Clinical and Molecular Hepatology

Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea

Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung,

Journal of Medical Virology.2019; 91(6): 1104. CrossRef

Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test

Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong

Journal of Medical Virology.2019; 91(12): 2158. CrossRef

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang

Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef

Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients

S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K

Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef

Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C

Isabella Esposito, Sebastián Marciano, Julieta Trinks

Expert Opinion on Drug Metabolism & Toxicology.2018; 14(6): 649. CrossRef

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study

Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae

Clinical and Molecular Hepatology.2017; 23(1): 51. CrossRef

Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis

Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh